Recently, Tai W et al., developed a lipid nanoparticle (LNP)-formulated mRNA-based T-cell-inducing antigen, which targeted three SARS-CoV-2 proteome regions that enriched human HLA-I epitopes (HLA-EPs), the sequences of HLA-EPs are highly conserved among SARS-CoV-2 variants, therefore, HLA-EPs induces broad cellular immunity and prevent SARS-CoV-2 infection (40), HLA-EPs would be one of new generations of COVID-19 vaccine, possibly can provide protection for individuals with HLA-B*15. This evidence concerns the gene HLA-B and COVID-19.